Prostate cancer and PARP inhibitors: progress and challenges

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), remains a lethal disease despite recent survival improvements.
• Alterations in DNA-damage response (DDR) genes are prevalent in advanced prostate cancers, indicating a potential therapeutic vulnerability.

Purpose of the Study:

• To review the rationale, development, and clinical application of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in prostate cancer.
• To discuss biomarker strategies and future challenges associated with PARP inhibitor therapy in mCRPC.

Main Methods:

• Literature review synthesizing data on PARP inhibitors in prostate cancer.
• Analysis of biomarker-based approaches and clinical trial outcomes.
• Discussion of current challenges and future directions for PARP inhibitor therapy.

Main Results:

• PARP inhibitors, such as olaparib, have demonstrated overall survival benefits in mCRPC patients with homologous recombination repair (HRR) deficiencies.
• The development of PARP inhibitors is supported by the synthetic lethality principle in tumors with DDR gene alterations.
• Biomarker-driven approaches are crucial for identifying patients likely to respond to PARP inhibitors.

Conclusions:

• PARP inhibitors represent a significant advancement in treating mCRPC, particularly for patients with specific genetic alterations.
• Further research and optimized clinical strategies are needed to overcome existing challenges and expand the use of PARP inhibitors.
• Personalized medicine approaches, guided by biomarkers, are essential for maximizing the efficacy of PARP inhibitors in prostate cancer treatment.